TY - JOUR
T1 - The carcinogenicity of opium consumption
T2 - a systematic review and meta-analysis
AU - M. Filho, Adalberto
AU - Turner, Michelle C.
AU - Warnakulasuriya, Saman
AU - Richardson, David B.
AU - Hosseini, Bayan
AU - Kamangar, Farin
AU - Pourshams, Akram
AU - Sewram, Vikash
AU - Cronin-Fenton, Deirdre
AU - Etemadi, Arash
AU - Glass, Deborah C.
AU - Rahimi-Movaghar, Afarin
AU - Sheikh, Mahdi
AU - Malekzadeh, Reza
AU - Schubauer-Berigan, Mary K.
N1 - Funding Information:
Michelle C. Turner is funded by a Ramón y Cajal fellowship (RYC-2017-01892) from the Spanish Ministry of Science, Innovation, and Universities and is co-funded by the European Social Fund. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. The IARC Monographs programme receives funding from the National Cancer Institute (3U01CA033193-38S1).
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/4
Y1 - 2023/4
N2 - The carcinogenicity of opium consumption was recently evaluated by a Working Group convened by the International Agency for Research on Cancer (IARC). We supplement the recent IARC evaluation by conducting an extended systematic review as well as a quantitative meta-analytic assessment of the role of opium consumption and risk for selected cancers, evaluating in detail various aspects of study quality on meta-analytic findings. We searched the published literature to identify all relevant studies on opium consumption and risk of selected cancers in humans through 31 October, 2022. Meta-relative risks (mRRs) and associated 95% confidence intervals (CIs) were estimated using random-effects models for studies of cancer of the urinary bladder, larynx, lung, oesophagus, pancreas, and stomach. Heterogeneity among studies was assessed using the I2 statistic. We assessed study quality and conducted sensitivity analyses to evaluate the impact of potential reverse causation, protopathic bias, selection bias, information bias, and confounding.In total, 2 prospective cohort studies and 33 case–control studies were included. The overall pooled mRR estimated for ‘ever or regular’ versus ‘never’ use of opium ranged from 1.50 (95% CI 1.13–1.99, I2 = 0%, 6 studies) for oesophageal cancer to 7.97 (95% CI 4.79–13.3, I2 = 62%, 7 studies) for laryngeal cancer. Analyses of cumulative opium exposure suggested greater risk of cancer associated with higher opium consumption. Findings were robust in sensitivity analyses excluding studies prone to potential methodological sources of biases and confounding. Findings support an adverse association between opium consumption and cancers of the urinary bladder, larynx, lung, oesophagus, pancreas and stomach.
AB - The carcinogenicity of opium consumption was recently evaluated by a Working Group convened by the International Agency for Research on Cancer (IARC). We supplement the recent IARC evaluation by conducting an extended systematic review as well as a quantitative meta-analytic assessment of the role of opium consumption and risk for selected cancers, evaluating in detail various aspects of study quality on meta-analytic findings. We searched the published literature to identify all relevant studies on opium consumption and risk of selected cancers in humans through 31 October, 2022. Meta-relative risks (mRRs) and associated 95% confidence intervals (CIs) were estimated using random-effects models for studies of cancer of the urinary bladder, larynx, lung, oesophagus, pancreas, and stomach. Heterogeneity among studies was assessed using the I2 statistic. We assessed study quality and conducted sensitivity analyses to evaluate the impact of potential reverse causation, protopathic bias, selection bias, information bias, and confounding.In total, 2 prospective cohort studies and 33 case–control studies were included. The overall pooled mRR estimated for ‘ever or regular’ versus ‘never’ use of opium ranged from 1.50 (95% CI 1.13–1.99, I2 = 0%, 6 studies) for oesophageal cancer to 7.97 (95% CI 4.79–13.3, I2 = 62%, 7 studies) for laryngeal cancer. Analyses of cumulative opium exposure suggested greater risk of cancer associated with higher opium consumption. Findings were robust in sensitivity analyses excluding studies prone to potential methodological sources of biases and confounding. Findings support an adverse association between opium consumption and cancers of the urinary bladder, larynx, lung, oesophagus, pancreas and stomach.
KW - Cancer
KW - Case–control study
KW - Cohort study
KW - Meta-analysis
KW - Opium
UR - http://www.scopus.com/inward/record.url?scp=85147743745&partnerID=8YFLogxK
U2 - 10.1007/s10654-023-00969-7
DO - 10.1007/s10654-023-00969-7
M3 - Review Article
C2 - 36773182
AN - SCOPUS:85147743745
SN - 0393-2990
VL - 38
SP - 373
EP - 389
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 4
ER -